HLAB*15:02 Genotyping

iPROMISE has developed a genotyping test kit for the detection of HLAB*15:02 variant, which has a high association with Steven-Johnson Syndrome (SJS) / toxic epidermal necrolysis (TEN). The Food and Drug Administration (FDA, USA) recommends that individuals of Asian ancestry be genotyped for the presence of the HLA-B*1502 variant prior to receiving carbamazepine or phenytoin to avoid adverse drug reactions

*we are currently in the process of applying for ISO 15189

Other Genotyping Services

VKORC1 : Warfarin resistance and sensitive
CYP2D6 : Ultra-rapid and poor metaboliser of antipsychotic drugs
CYP2C19 : Clopidogrel resistance
CYP3A5 : Tacrolimus toxicity
CYP2C9 : Warfarin and NSAIDs toxicity

Contact Us

Integrative Pharmacogenomics Institute (iPROMISE)
Level 7, FF3 Building, UiTM Selangor Branch

Puncak Alam Campus, 42300 Bandar Puncak Alam
Selangor Darul Ehsan. M A L A Y S I A

Email :

Tel : +603-3258 4652